GKOS Earnings Date: Feb 16, 2027 (Estimated) — Glaukos Corporation
NYSE · Healthcare · Medical Devices
Updated
When is GKOS's next earnings date?
Glaukos Corporation (GKOS) is expected to report Q4 2026 earnings on Tuesday, February 16, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.11 on revenue of $186.6M.
How did GKOS do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Glaukos Corporation posted EPS of $0.47 versus the -$0.10 estimate, a beat of 587.8%. Revenue was $211.0M against a $168.0M estimate. The stock's 1-day post-earnings move was +33.6%.
How much does GKOS stock move after earnings?
GKOS beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 16.0% (up or down) in the day after earnings.
About Glaukos Corporation
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
🤖 AI Earnings Analysis
Glaukos delivered a strong, revenue-led quarter: sales rose 57% year over year to $211M, beating estimates by $43M, while EPS swung to $0.47 from a $0.16 loss. Operating income remained negative at $16M, tempering the headline beat for this medical-device growth story.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -0.10 | 0.47 | +587.75% | $211.0M | ✅ Beat | +33.65% | — | — |
| 2026-07-29 | Q2 2026 | -0.23 | -0.14 | +39.13% | $185.6M | ✅ Beat | +4.24% | +5.73% | +12.53% |
| 2026-04-29 | Q1 2026 | -0.28 | -0.18 | +35.71% | $150.6M | ✅ Beat | +22.84% | +15.65% | -11.64% |
| 2026-02-17 | Q4 2025 | -0.21 | -0.28 | -33.33% | $143.1M | ❌ Miss | +13.47% | +11.75% | -3.21% |
| 2025-10-29 | Q3 2025 | -0.26 | -0.16 | +38.46% | $133.5M | ✅ Beat | +13.89% | +9.42% | +37.88% |
| 2025-07-30 | Q2 2025 | -0.26 | -0.24 | +7.69% | $124.1M | ✅ Beat | -8.46% | -5.91% | +2.67% |
| 2025-04-30 | Q1 2025 | -0.35 | -0.22 | +37.14% | $106.7M | ✅ Beat | -11.36% | -6.38% | +0.04% |
| 2025-02-20 | Q4 2024 | -0.39 | -0.40 | -2.56% | $105.5M | ❌ Miss | -20.01% | -24.80% | -35.02% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY20 · $73.2M total
| Segment | Share | Revenue | YoY | Q2 FY20 | Q3 FY20 | Q4 FY20 |
|---|---|---|---|---|---|---|
| Glaucoma | 79.7% | $58.4M | — | $24.9M | $51.9M | $58.4M |
| Corneal Health | 20.3% | $14.9M | — | $6.6M | $12.9M | $14.9M |
By region
Q3 FY26 · $211.0M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 82.9% | $174.8M | +72.3% | $75.1M | $90.5M | $101.5M | $108.0M |
| Non-US | 17.1% | $36.2M | +12.8% | $31.6M | $33.6M | $32.1M | $35.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.